CORDIS
EU research results

CORDIS

English EN

Additive Printing for Cell-Based Analysis

Objective

The Project shall develop a unique manufacturing solution for the automated production of complex cell models widely used by industry to test biological activity and biosafety. No means of scalable manufacture presently exists.
The technical solution is to assemble cell models by additive manufacturing; to control the resident cells’ locations within these 3D models; to supply the models to customers as pre-assembled, frozen products. The result shall be an analytical tool which, unlike current practice, does not compromise analytical output for convenience, but combines high predictive value and low cost with exceptional user-friendliness.
The solution is unique, proprietary and highly positive-disruptive in its industrial sector. Its achievement will be measurable in this Project as an exemplifying, printed hepatotoxicity assay with wide application in drug discovery and biosafety testing. An SME Instrument Phase 1 Project advanced the core printing technology delivering this solution to TRL7, and developed a business plan for its exploitation.
That business plan confirmed the wide, cross-industry application of cell-based analysis, from preclinical drug discovery through natural products/food to medical devices and nanosafety, and mapped the advantages of additively-manufactured products onto demonstrable industry trends and customer needs.
The business plan and its underpinning technology are founded in the applicant’s long-term strategic goals, evidenced by profitable business in the target market from proprietary cell-based services, and by ancillary technology developments, also to TRL7 and supported by UK national funding, which create unique competitive advantage.
The outcome of this Phase 2 Project will be a mature cell-based manufacturing technology, its demonstrable application in a commercial environment, and the assembly of a corporate infrastructure ready to take the Project’s manufacturing solution into a well-scoped and lucrative marketplace.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

AvantiCell Science Ltd

Address

Gibbsyard Building
Ka6 5hw Ayr

United Kingdom

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 1 262 560,43

Project information

Grant agreement ID: 697804

Status

Closed project

  • Start date

    1 November 2015

  • End date

    31 October 2018

Funded under:

H2020-EU.2.3.1.

H2020-EU.2.1.2.

  • Overall budget:

    € 1 803 657,75

  • EU contribution

    € 1 262 560,43

Coordinated by:

AvantiCell Science Ltd

United Kingdom